The FDA’s Oncologic Drugs Advisory Committee recently voted to narrow the label for checkpoint inhibitors Keytruda and Opdivo ...

The European Commission (EC) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with the ...

Bristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo ...

It covers all indications on the current Opdivo label for adults with solid tumours, including as monotherapy, for maintenance following completion of the checkpoint inhibitor plus Yervoy ...

benefit when Opdivo (nivolumab) is used with platinum-doublet chemotherapy as a neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC) patients. The open-label, randomised ...

European Commission approves Bristol Myers Squibb’s Opdivo plus Yervoy for first-line treatment of adult patients with unresectable or advanced HCC: Princeton, New Jersey Monday ...

Opdivo plus Yervoy showed a median overall survival of 23.7 months vs. 20.6 months with lenvatinib or sorafenib in the CheckMate -9DW trial. The overall response rate for Opdivo plus Yervoy was 36 ...

BMY is banking on new drugs to offset generic competition for older drugs. However, this might not be enough as the outlook ...

CheckMate-816 is a randomized, open-label, multi-center trial which is evaluating the efficacy of Opdivo in combination with chemotherapy versus chemotherapy alone as a neoadjuvant treatment for ...

Opdivo, on a standalone basis, is also approved for a plethora of oncology indications. It continues to maintain momentum on consistent label expansions. The FDA approval of Opdivo Qvantig ...